In the COO position, Pierre Bourdage has leadership responsibility for the overall Sandoz pipeline strategy and choices, BD&L priorities and decisions, and end-to-end new product value delivery. 

During his time at Sandoz, Pierre has redefined the global strategy across clear therapy areas including complex and underserved biologics. He launched an integrated new portfolio process that drives portfolio selection and evaluation, including adding five biosimilars to pipeline in less than 9 months. Sandoz now has eight approved biosimilars in total, including three that were launched in 2018, and continues to invest and expand a leading biosimilar pipeline.  

Off-patent medicines offer a huge potential and opportunity to bring value by increasing access for patients to affordable medicines, reducing inequalities in healthcare provision and delivering savings to healthcare systems that can be reinvested to support better patient outcomes.

Pierre brings considerable experience in launch excellence and team leadership as well as brand and franchise management with over 20 years in the pharmaceutical and healthcare industry. He has a passion for engaging and mobilizing high performing matrixed teams and is skilled at developing clear and fluid strategic plans that create and sustain value.